Download MendeleyProfiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.
Damghani, T., Chitnis, S.P., Abidakun, O.A., Patel, K.B., Lin, K.S., Ouellette, E.A., Lantry, A.M., Heppner, D.E.(2025) J Med Chem 68: 17917-17932
- PubMed: 40801664
- DOI: https://doi.org/10.1021/acs.jmedchem.5c01661
- Primary Citation of Related Structures:
9MSR, 9MSS, 9MST, 9NHW, 9NIS, 9NJ7, 9NJN, 9NM0, 9OS6 - PubMed Abstract:
Targeted covalent inhibitors (TCIs) are actively pursued in drug discovery due to their prolonged target engagement and clinical efficacy. Although kinetic parameters provide a path to their optimization, systematic design strategies and practical guidance remain underexplored. In this study, the EGFR kinase is deployed as a model system to elucidate structural and functional determinants critical for directing the optimization of irreversible TCIs. Functional analyses reveal a two-phase optimization process, underscoring the importance of balancing─rather than maximizing─the inactivation efficiency rate ( k inact / K I ). Selective inhibition of the oncogenic L858R/T790M mutant over the wild-type is achieved by tuning this balance, particularly for TCIs exhibiting the fastest k inact / K I . Structural studies indicate that certain hydrophobic and hydrophilic interactions are associated with L858R/T790M selectivity, offering insights into structure-guided design. These results offer a broadly applicable approach for prioritizing compounds and support the integration of kinetic and selectivity data in TCI discovery campaigns.
- Department of Chemistry, The State University of New York at Buffalo, Buffalo, New York 14260, United States.
Organizational Affiliation:
